This is a multicenter, non-interventional, observational real-world study to evaluate the efficacy and safety of Taletrectinib in ROS1-positive non-small cell lung cancer (NSCLC) following Entrectinib progression. Patients deemed eligible for Taletrectinib by their physicians were enrolled after providing informed consent. Taletrectinib will be administered according to clinical practice and data on treatment patterns, clinical outcomes, and safety will be collected during routine evaluations.
Age ≥ 18 years.
Histologically or cytologically metastatic NSCLC (UICC/AJCC TNM Staging System, 9th Edition, Stage Ⅳ).
At least one measurable target tumor lesion as accessed by RECIST v1.1 criteria.
Documented ROS1 gene fusion identified by an approved molecular testing method (FISH, RT-PCR, or NGS).
Patients with driver gene mutations/alterations that have approved targeted therapies , including but not limited to EGFR, ALK, RET, etc.
Currently participating in other interventional clinical trials or having received investigational drug treatment within 4 weeks prior to enrollment .
Pregnancy or breastfeeding.
Patients with uncontrolled co-morbidities who are assessed by the investigator not to receive targeted therapy.
Patients with ROS1-positive non-small cell lung cancer (NSCLC) who progressed following Entrectinib treatment
Cohort
Prospective
Taletrectinib
DrugTaletrectinib, 600mg, QD
ORR
Objective response rate
PFS
Description: Progression free survival
DoR
Duration of response
DCR
Disease control rate
OS
Overall survival
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
